Locoregional therapy of oligometastatic breast cancer

Summary Oligometastastic disease has been defined as not more than five metastases found in radiological workup within not more than two different distant organs of the body [1]. Starting in 1995, several authors claimed that local treatment, especially radiotherapy, may have a positive impact on oligometastatic patients. However, prospective trials demonstrated that local therapy of nonsymptomatic metastases should not be routinely offered as there is no survival benefit. Surgical resection of primary breast cancer in synchronous stage IV disease should also not be offered. However, there is a window of opportunity for men and women with synchronous oligometastatic disease where a true R0 resection by treating metastases as well as the primary cancer may be achieved. These cases need to be discussed within a multidisciplinary team (MDT) conference and should be included in new trials.

Authors

Institutions

Publication Details

Journal
memo - Magazine of European Medical Oncology
Published
2024-11-26
DOI
https://doi.org/10.1007/s12254-024-01008-1
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Locoregional therapy of oligometastatic breast cancer

Florian Fitzal
memo - Magazine of European Medical Oncology
Breast Cancer Treatment Studies
article

Locoregional therapy of oligometastatic breast cancer

Florian Fitzal
article en

Abstract

Summary Oligometastastic disease has been defined as not more than five metastases found in radiological workup within not more than two different distant organs of the body [1]. Starting in 1995, several authors claimed that local treatment, especially radiotherapy, may have a positive impact on oligometastatic patients. However, prospective trials demonstrated that local therapy of nonsymptomatic metastases should not be routinely offered as there is no survival benefit. Surgical resection of primary breast cancer in synchronous stage IV disease should also not be offered. However, there is a window of opportunity for men and women with synchronous oligometastatic disease where a true R0 resection by treating metastases as well as the primary cancer may be achieved. These cases need to be discussed within a multidisciplinary team (MDT) conference and should be included in new trials.

memo - Magazine of European Medical OncologyVol. 18(1)
Hanusch Hospital (AT), Medical University of Vienna (AT)
Medizinische Universität Wien
Good health and well-being
Openalex Percentile: Top 69%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Locoregional therapy of oligometastatic breast cancer — Florian Fitzal · memo - Magazine of European Medical Oncology (2024) | TGRS Research Map | TGRS